Jen Mills

Healthcare junkie. Passionate about patient advocacy. Food and travel lover. VP Patient & Prof. Partnerships at FMI. All opinions expressed are my own.

[Petros Grivas @PGrivasMDPhD]

Very important talk on disparities in prostate Ca:not much explained by genomic alterations but access to NGS, clinical trials & other determinants!We can do better as a field! @HalaBorno @OncoAlert #ASCO2021 @ASCO @NarjustDumaMD @neerajaiims @TiansterZhang @montypal @DrChoueiri

[Jen Mills @JenMillsAU]

#ASCO2021

[Jen Mills @JenMillsAU]

Proud to be a part of this important dialogue at ASCO.
https://t.co/zGb3MmAxyX

[Foundation Medicine @FoundationATCG]

"The addition of FoundationOne Tracker for research use provides our biopharma and academic partners access to Foundation Medicine’s broad, advanced-stage CGP footprint," says Foundation Medicine Chief Scientific Officer @PritiHegde. Read more: https://t.co/rrdJ43MsHC

[Foundation Medicine @FoundationATCG]

Today at #ASCO21: New data suggest limited access to early comprehensive genomic testing and clinical trials in patients of African descent may help explain disparities in #ProstateCancer care. Learn more: https://t.co/eRsu0KdCyp

[Foundation Medicine @FoundationATCG]

In recognition of #LabWeek we participated in @TheWRP4LC for lung cancer awareness. Our lab employees took photos with a white ribbon created and provided by patient advocates @heidi_onda, Pierre Onda, and @bjork5. #LabWeek #WeAreFMI

[Jen Mills @JenMillsAU]

Always terrific insights from @PritiHegde: the current and future science of genomic testing, building long term relationships with patients, and helping young women scientists get a seat at the right table. #lcsm

[Dave Bjork @bjork5]

Excited for this episode with @PritiHegde talking about the value of genomic profiling in #lungcancer And about building long term relationships with patients. @FoundationATCG @cindy_perettie @chrisdraft
@BrendonStilesMD #lcsm @CharuAggarwalMD #LCSM
https://t.co/Xg6dED0bFH

[Jen Mills @JenMillsAU]

Exciting annct that the first #rarecancer patients are enrolled in this important and innovative study addressing access issues for genomic testing. With @BayerPharma @targetcancer

[TargetCancer Fdn @targetcancer]

Join @targetcancer for a special #RareCancerDay webinar about TRACK, our new precision medicine of #rarecancer clinical study, featuring TRACK investigators @Dr_R_Kurzrock and @RGroisberg, as well as @xelamb from @FoundationATCG. View it on demand: https://t.co/I9Wu8YOCCF

[Jen Mills @JenMillsAU]

Webinar TONIGHT for men w/ prostate Ca: "Genomic & Genetic Testing for Active Surveillance Decision Making," from @ancan501c3 @UsTOOHQ @PCRIhome @ZEROCancer @CancerABCs & Prostate Ca Int'l, with Dr. Brian Helfand from @NorthwesternU & @NorthShoreWeb. https://t.co/bmtnAZGp8n

[Jen Mills @JenMillsAU]

Congratulations to a visionary leader, @bonniejaddario. So proud to know you and to work with you!

[GO2 for Lung Cancer @GO2forLungCancr]

Congratulations to our own @bonniejaddario for receiving the Lifetime Achievement Award from @cure_magazine. We are so proud! Bonnie’s awe-inspiring message of empowerment has reached millions. https://t.co/sxg2HmaoRt

[Bonnie J. Addario @bonniejaddario]

NSCLC patients should receive comprehensive biomarker testing more than once! Andrew Ciupek, clinical research manager @GO2Foundation, says retesting can help identify the best method of treatment as a patient’s cancer changes over time. @cure_magazine https://t.co/z1sHlGz6su

[Brian Alexander @xelamb]

F1LCDx approval includes @clovisoncology rucaparib companion diagnostic for patients with BRCA mutant mCRPC #pcsm (thanks @subatomicdoc @mtmdphd and @drdonsdizon and team # table!)
https://t.co/gsSjNfQrJn

[TargetCancer Fdn @targetcancer]

Many thanks to @NTRKers for a fantastic webinar this morning discussing the importance of comprehensive genomic profiling to identify rare fusions like #NTRK. Grateful for your advocacy! #precisionmedicine

[Foundation Medicine @FoundationATCG]

This week, our team will share how the science came full circle from the identification of METex14 alterations in our database to the FDA approval of a targeted therapy for patients w/ METex14 in #NSCLC. Tune in to @TABRECTA_US on July 14 & 15 at 8 p.m.: https://t.co/NN1zsIMnqr

[Jen Mills @JenMillsAU]

Thank you, thank you, thank you. We couldn't do what we do without you, @ancan501c3 @peggyddennis @sweetlenox1 @sarahkrug1 And remembering the irrepressible @don450sl.

[Foundation Medicine @FoundationATCG]

This #CancerSurvivorMonth, we thank our Patient Community Council for helping us keep patients at the heart of everything we do. Every day, they inspire us to continue working to transform #CancerCare.

[Foundation Medicine @FoundationATCG]

“Lexent Bio’s platforms align well with our liquid biopsy R&D strategy, which ultimately aims to bring the latest research innovations into routine clinical use...& at potentially earlier stages of patient care,” said CEO Cindy Perettie. Learn more: https://t.co/12ieYjXtzz

[Foundation Medicine @FoundationATCG]

#LiquidBiopsy was once an improbable idea. Today it’s ripe with
potential. Read our blog to get answers to commonly asked
questions. https://t.co/YGUqsT1TS5

[Janet Freeman-Daily @JFreemanDaily]

#ASCO20 docs: Pls consider directing patients w/oncogene-driven #cancer (EGFR ALK ROS1 RET NTRK etc) to oncogene support groups on FB/web: @ros1cancer @EGFRResisters @ALKLungCancer @alk_fusion @Exon20Group RET Renegades @kRasKickers @METCrusaders @NTRKers
#ASCO2020 #ASCO20VR

[National Cancer Institute @theNCI]

How does #COVID19 affect people with cancer? NCI plans to find out through a long-term, nationwide study: https://t.co/36v1jk2xO9 #NCCAPS #coronavirus

[Cindy Perettie @cindy_perettie]

Great news! Congrats to everyone who made this happen. I’m thrilled for #prostatecancer patients who will now have another treatment option. #PrecisionMedicine